New Frontier Data Study Foresees U.S. Cannabis Consumer Demographic Surging to 71 Million by 2030
by Bethan Rose
Ohio is currently accepting petitions in an attempt to expand the list of qualifying conditions for medical cannabis. But this has failed in the past and could prevent measures from moving forward this time unless new research could be presented to sway the state medical board’s decision. The 34th largest state by area and the seventh most populated state in our country is Ohio, aka the Buckeye state. Ohio became the 25th state to legalize medical cannabis back on June 8 of 2016. Medical cannabis is now available to residents in Ohio who meet one of 22 qualifying conditions laid out by House Bill 523.
Of the current 22 qualifying conditions to receive a legal recommendation for medical cannabis, opioid use disorder, Autism Spectrum Disorder, and anxiety are not on that list. Advocates have tried to make this happen in the past partitioning for the addition of these three conditions, but they were ultimately denied by the state’s medical review board.
In regard to the petition to add these three conditions to state law, advocates must be very careful. According to the Ohio State Medical Marijuana website, the petition will not be considered if received after December 31, 2020, if it seeks to add a broad category of diseases or conditions, or if the condition is one that has been previously reviewed by the board and rejected unless new scientific research that supports the request is offered.
Since these conditions have been denied in the past, advocates must meet very specific guidelines to try to get them approved this time. The state website says,
“If you are petitioning for a previously considered condition, do not resubmit documents which have already been reviewed by the board, and only new scientific research should be submitted for previously rejected petitions.”
Back in 2019, it seemed as though advocates might have had things going in their favor to add Autism Spectrum Disorder and anxiety to this list of qualifying conditions. However, that forward momentum was short-lived. Several physicians gave their input and were the deciding factors in helping prevent the addition of these two conditions to the qualifying list. One, in particular, Dr. Anup Patel is the most perplexing.
Dr. Patel is a member of the Nationwide Children’s Hospital. He ran clinical trials for big pharma’s GW Pharmaceuticals research division on Epidiolex. Epidiolex is an FDA approved cannabis-based pharmaceutical manufactured drug used in the treatment of seizures. Yet Dr. Patel held the view that there is little to no gold standard research to prove cannabis effectively helps treat anxiety or Autism. It seems incredibly conflicting that a medical professional can lead research on cannabis medicine that finds FDA approval yet turn around and say that cannabis has no proof of being effective?
In the opinion of this writer, physicians like Dr. Patel are bought and paid for. It is maddening to see medical professionals clinging to the destructive addictive past of pharmaceuticals without open acceptance to plant medicine. It’s frustrating scenarios such as this that have contributed to the failed War on Drugs and have cost the United States countless billions of wasted tax dollars in the process.
In fact, cannabis has shown potential in managing Autism. In October of 2019, just two months after Dr. Patel made his opinionated viewpoint about the lack of proof of effectiveness in cannabis to treat Autism, the US National Library of Medicine National Institutes of Health had a research paper published that suggested Dr. Patel was wrong.
The study is titled, “Effects of CBD-Enriched Cannabis sativa Extract on Autism Spectrum Disorder Symptoms: An Observational Study of 18 Participants Undergoing Compassionate Use” and is published on the NCBI. It revealed that,
“Overall, mostly positive outcomes were reported for the 15 patients that adhered to the standardized CE treatment (one case for six months and 14 cases for nine months), especially regarding improvements in sleep disorders, seizures, and behavioral crisis. Also, signs of improvement were reported for motor development, communication and social interaction, and cognitive performance.”
Maybe there were just enough lacking studies at the time for Dr. Patel to support denying the addition of Autism, anxiety, and opioid dependency to the list of qualifying conditions in Ohio. But here in 2020, that is not the case. Should the medical board in Ohio deny adding these conditions to the state’s list, it may be time to change who sits on this board. Last year Dr. Patel said, “the State Medical Board of Ohio is relying on traditional medicine.” Let’s see if this draconian stance is still supported this year and, if so, by who.
Cannabis, like any plant or herb stored and used for consumption, has a shelf life. This means that cannabis can go bad, get moldy, and lose potency when stored improperly or simply from age. When cannabis is stored properly, it can last anywhere from six months to a year depending on your storage equipment and…
Hydroponic systems are a popular alternative to the more traditional means of growing cannabis. Hydroponics allows cannabis to be grown without the use of soil and can yield a significant amount of bud, but it comes with more maintenance and risks. Regardless, some growers believe the benefits of hydroponics are worth the laborious process. One…
A new report from the United Nations Office on Drugs and Crime (UNODC) suggests that cannabis consumption levels soared amid COVID-19 lockdowns and wide-ranging legalization. The findings were published in the organization’s annual World Drug Report. “Cannabis legalization appears to have accelerated the upwards trends in reported daily use of the drug,” reads an excerpt…
A U.S. Senate leader introduced a federal legalization bill, Brittney Griner’s Russian court proceedings began, and Zimbabwe legalized hemp products. Let’s dive into this week’s cannanews. Sen. Schumer Introduces Federal Legalization Bill Senate Majority Leader Chuck Schumer has finally introduced his long-awaited federal cannabis legalization bill. Titled the Cannabis Administration and Opportunity Act (CAOA), the…
Michigan is mourning the loss of a prominent cannabis advocate, an American man’s family is fighting to bring him home from Russian prison, and a bill designed to aid veterans had a tumultuous journey through Congress. Let’s dive into this week’s cannanews. Michigan Remembers Late Cannabis Activist Zahra Abbas Last week, Michigan’s Democratic Party Cannabis…
A new study is set to examine the use of cannabis for anxiety. The collaborative effort between CannaMD, Florida Gulf Coast University,…